Gemfibrozil

BreastfeedingPediatric
  • TRADE NAMES: Bolutol; Decrelip; Fibrocit; Gemlipid; Gen-Fibro; Gevilon Uno; Jezil; Lipur; Lopid (Pfizer); Nu-Gemfibrozil
  • INDICATIONS: Hyperlipidemia
  • CLASS: Fibrate, Lipid regulator
  • HALF-LIFE: 2 hours

Contra-indicated in patients with preexisting gallbladder disease.

Our database has 31 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
NAILS.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
OTHER.


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top